No Transformants in the Teaching Lab
A postgraduate lab wants to clone a 2.1 kb gene into pUC19. The gene was amplified with primers carrying EcoRI and BamHI sites. The vector was cut with EcoRI and BamHI, dephosphorylated, and ligated overnight at 16°C. Competent E. coli DH5α were heat-shocked, plated on LB agar with 100 µg/mL ampicillin, IPTG and X-gal, and incubated at 37°C. After 20 hours there are 12 blue colonies and no white colonies on the test plate; the vector-only plate has 300 blue colonies. The insert contains an internal EcoRI site. The ligase used was from a freezer box that had thawed during a power cut; the T4 ligase buffer was refrozen three times. The lab plans to repeat the same experiment with fresh ligase. The department biosafety committee asks whether the work needs BSL-2 and how the recombinant waste will be handled.
1. Why will repeating with fresh ligase alone probably fail? Redesign the cloning strategy.
Read the worked answer
Fresh ligase addresses only one variable. The decisive problem is that the insert contains an internal EcoRI site. Digestion of the PCR product with EcoRI cuts the 2.1 kb insert internally, so the ligation cannot assemble an intact insert; even if a fragment ligates, the full-length gene is not reconstructed. The 12 blue colonies and 300 blue colonies on the vector-only plate show that the vector preparation, dephosphorylation, transformation and blue-white selection are working; they do not indicate a successful insert.
Redesign by restriction-mapping the insert and choosing two enzymes absent from it, for example BamHI plus SalI or NotI, adding those sites through the primers. If EcoRI must be used, use a partial digest so some molecules are cut only at the terminal site, or switch to Gibson assembly, In-Fusion or TA cloning. Sequence-verify the junctions and the entire insert, and check orientation. Also use fresh ligase and buffer, but treat that as a secondary fix. The redesigned experiment should include a ligation with a known insert to prove the system works.
2. What controls would you add to distinguish ligation failure from transformation or selection failure?
Read the worked answer
Add a vector-only ligation control: it should give blue colonies, confirming that self-ligation and selection are working. Add a no-insert ligation and a ligation with a known 1 kb insert that has already worked; the latter should give white colonies if the ligation and plating system are functional. Transform uncut supercoiled pUC19 to measure competent-cell efficiency; a good DH5α preparation should give many more colonies than the vector-only ligation. Plate a sample without ampicillin to check cell viability. Include a ligase activity test with lambda HindIII fragments. Use colony PCR with insert-specific primers and restriction digestion of plasmid minipreps to confirm any white colonies. If vector-only gives blue colonies but the known insert gives none, the problem is ligation or insert quality. If no colonies appear on ampicillin even with supercoiled plasmid, the problem is transformation, ampicillin selection or incubation.
3. Respond to the biosafety committee: what containment level, waste handling and conditions apply?
Read the worked answer
E. coli DH5α is a non-pathogenic K-12 derivative and is normally BSL-1. A pUC19 derivative carrying a non-pathogenic plant gene is also generally BSL-1 under standard rules, but the institutional biosafety committee may require BSL-2 for all recombinant DNA work; follow the stricter local rule. Work on a clean bench, avoid aerosol-generating operations, and keep the recombinant strain out of the environment. Autoclave all plates, liquid cultures, tips and contaminated plastic before disposal; disinfect surfaces with 70% ethanol or a suitable disinfectant. Do not pour cultures down the sink. Keep a glycerol stock inventory and a waste log. The ampicillin-resistance marker is a laboratory selection marker, not a reason for BSL-2 by itself, but it must not be released. If the gene function is unknown or the construct could increase fitness, reassess the risk before scaling up.